• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    South Korea Inflammatory Bowel Disease Treatment Market

    ID: MRFR/HC/54706-HCR
    200 Pages
    Garvit Vyas
    September 2025

    South Korea Inflammatory Bowel Disease Treatment Market Research Report By Drug Type (Aminosalicylates, Corticosteroids, Immunomodulators, Biologics, Antibiotics), By Route of Administration (Oral, Injectable, Topical), By Disease Type (Ulcerative Colitis, Crohn's Disease) and By End User (Hospitals, Ambulatory Surgical Centers, Homecare Settings)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    South Korea Inflammatory Bowel Disease Treatment Market Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Summary Table of Contents Segmentation Infographic

    South Korea Inflammatory Bowel Disease Treatment Market Summary

    The South Korea Inflammatory Bowel Disease Treatment market is projected to grow from 423.8 million USD in 2024 to 625 million USD by 2035.

    Key Market Trends & Highlights

    South Korea Inflammatory Bowel Disease Treatment Key Trends and Highlights

    • The market is expected to reach 625 million USD by 2035, indicating a robust growth trajectory.
    • From 2025 to 2035, the market is anticipated to grow at a compound annual growth rate of 3.6 percent.
    • In 2024, the market valuation stands at 423.8 million USD, reflecting the current demand for treatment options.
    • Growing adoption of advanced therapeutic options due to increasing prevalence of inflammatory bowel disease is a major market driver.

    Market Size & Forecast

    2024 Market Size 423.8 (USD Million)
    2035 Market Size 625 (USD Million)
    CAGR (2025-2035) 3.6%

    Major Players

    Pfizer, Ferring Pharmaceuticals, Astellas Pharma, Celgene, Sandoz, Mylan, Sanofi, Merck, Lupin Pharmaceuticals, Roche, AbbVie, Amgen, Takeda Pharmaceutical, Bristol Myers Squibb, Johnson & Johnson

    South Korea Inflammatory Bowel Disease Treatment Market Trends

    The South Korea Inflammatory Bowel Disease Treatment Market is observing noteworthy shifts fueled by the growing awareness and the increasing rate of IBD (internally billed diagnostics) tests being performed, including for Crohn’s disease and ulcerative colitis. Health promotion activities as a part of chronic disease management are on the rise, which is supported by the Korean government, to enhance the early diagnosis and IBD treatment which is making more people to consult doctors.

    The increasing incidence of IBD in South Korea is indicating the growing demand for enhancement in the treatment options, which is forcing the healthcare providers to revise the treatment protocols and adopt new therapies. There is a high degree of unexplored opportunities with the advancements in personalized medicine and biologic therapies in South Korea.

    The increasing focus of pharmaceutical companies on developing targeted therapies is changing the approaches to treatment. Also, treatment modalities incorporate new technologies, such as telemedicine and remote patient monitoring, which helps with the management of the patients and therapy adherence. The shift towards a more patient-friendly care model opens up new avenues for service and solution delivery.

    Lately, there has been a significant rise in the collaborative research projects undertaken by academia, medical care providers, and industry partners. This collaboration is intended to better understand IBD and to devise applicable therapeutics that are suitable for the South Korean context.

    Moreover, the South Korean Ministry of Food and Drug Safety’s provides regulatory support for enabling expeditious approval of novel therapies, which ensures that new treatments are available more rapidly to patients. All of these are signs that South Korea’s IBD market has a promising and transforming trend.

    Market Segment Insights

    Inflammatory Bowel Disease Treatment Market Drug Type Insights

    The South Korea Inflammatory Bowel Disease Treatment Market based on Drug Type encompasses a variety of therapeutics aimed at managing conditions such as Crohn's disease and ulcerative colitis. This segment includes Aminosalicylates, which play a crucial role in treating mild to moderate inflammation; they are often considered the first line of treatment due to their effectiveness and relatively fewer side effects.

    Corticosteroids are another vital component within this market segment, primarily used to manage severe symptoms by rapidly reducing inflammation, albeit with careful consideration due to potential long-term effects. The growing development within the field of Immunomodulators showcases their importance, as they work by suppressing the immune response, thus providing a more consistent management option for patients who do not respond to conventional therapies.

    Biologics have significantly transformed treatment paradigms in South Korea, representing advanced therapies that specifically target immune pathways and offer new hope to patients with refractory conditions. This innovation has led to increasing acceptance and reliance on these medications, driven by promising clinical outcomes.

    Meanwhile, Antibiotics are included as they help manage secondary infections that can complicate inflammatory bowel diseases, ensuring a comprehensive approach to patient care. Factors such as the rising prevalence of inflammatory bowel diseases in South Korea, driven by lifestyle changes and environmental factors, amplify the need for effective drug therapies.

    Consequently, healthcare policies that support drug accessibility and reimbursement are pivotal in shaping the South Korea Inflammatory Bowel Disease Treatment Market dynamics. With continuous research and development efforts, growth is poised in this sector as new formulations and treatment guidelines emerge, responding to patient needs and enhancing the quality of life for those affected.

    Inflammatory Bowel Disease Treatment Market Route of Administration Insights

    The Route of Administration segment within the South Korea Inflammatory Bowel Disease Treatment Market plays a crucial role in the management and treatment of conditions such as Crohn's disease and ulcerative colitis. The segment is primarily categorized into Oral, Injectable, and Topical administrations, with each presenting unique advantages and challenges.

    Oral administration remains significant due to its ease of use and patient compliance, making it a preferred choice for long-term treatment regimens. Injectable treatments are increasingly utilized for their rapid onset of action and effectiveness, especially in severe cases, while topical formulations provide targeted relief for localized symptoms, though they are less commonly used.

    As the South Korean population becomes more health-conscious and seeking advanced therapies, innovation in drug delivery routes is expected to thrive. Overall, advancements in these administration methods align closely with evolving patient needs and preferences, making this segment essential for addressing the diverse challenges associated with inflammatory bowel disease management.

    Furthermore, the South Korea Inflammatory Bowel Disease Treatment Market statistics indicate an ongoing expansion as healthcare providers emphasize personalized treatment plans tailored to individual patient requirements.

    Inflammatory Bowel Disease Treatment Market Disease Type Insights

    The South Korea Inflammatory Bowel Disease Treatment Market is poised to address significant health challenges associated with various disease types, prominently featuring Ulcerative Colitis and Crohn's Disease. Ulcerative Colitis, characterized by inflammation of the colon, has garnered significant attention within the healthcare sector due to its rising prevalence.

    Its management involves a comprehensive approach, encompassing medications, dietary adjustments, and sometimes surgical interventions. On the other hand, Crohn's Disease affects any part of the gastrointestinal tract and presents unique challenges, often requiring more intensive treatment regimens.

    The patient's quality of life and the complexities of symptom management further underscore the importance of advancing treatment options in this category. The increasing recognition of these conditions in South Korea, coupled with heightened research and development initiatives, signifies a growing market trajectory.

    Collaboration among healthcare professionals, pharmaceutical companies, and research institutions is expected to drive innovation in therapeutic solutions. Moreover, the government is actively supporting initiatives aimed at improving the understanding and treatment of inflammatory bowel diseases, thereby enhancing overall patient outcomes and paving the way for more tailored therapies in the future. The focus on these disease types reveals their critical role in the broader landscape of the South Korea Inflammatory Bowel Disease Treatment Market.

    Inflammatory Bowel Disease Treatment Market End User Insights

    The South Korea Inflammatory Bowel Disease Treatment Market exhibits significant activity across its End User segment, which includes Hospitals, Ambulatory Surgical Centers, and Homecare Settings. Hospitals are typically the primary setting for comprehensive care, catering to acute cases and providing advanced treatment options such as surgical interventions and intensive monitoring.

    Ambulatory Surgical Centers, on the other hand, offer a more cost-effective and efficient platform for outpatient procedures, becoming increasingly popular as they provide patients with quicker access to necessary treatments. Lastly, Homecare Settings contribute substantially to the market by enabling patients to receive care in a familiar environment, which often results in better adherence to treatment regimens and improved quality of life.

    The growing prevalence of Inflammatory Bowel Disease in South Korea drives the demand across these categories, highlighting the importance of tailored therapeutic approaches. Factors such as demographic shifts and an increasing focus on patient-centered care further influence the dynamics within these settings, making them pivotal to the overall treatment landscape.

    As a result, these end users are essential for addressing the diverse needs of patients with inflammatory bowel disease, emphasizing their critical role in the South Korea Inflammatory Bowel Disease Treatment Market.

    Get more detailed insights about South Korea Inflammatory Bowel Disease Treatment Market

    Request Free Sample

    Key Players and Competitive Insights

    The South Korea Inflammatory Bowel Disease Treatment Market is characterized by significant growth driven by the rising prevalence of conditions such as Crohn's disease and ulcerative colitis. The market is influenced by various factors including the increasing awareness of these diseases, advancements in treatment options, and a growing emphasis on personalized medicine.

    With a mix of multinational and local companies operating in the market, competition is intense. Companies are focusing on research and development to enhance therapeutic efficacy and minimize side effects of treatments.

    This competitive landscape is further shaped by strategic collaborations, partnerships, and potential mergers and acquisitions, as firms seek to expand their market presence and enhance their product offerings. Pfizer has established a strong foothold in the South Korean Inflammatory Bowel Disease Treatment Market through its extensive portfolio of approved therapies designed to manage these chronic conditions.

    The company's strengths lie in its robust research and development capabilities, which have enabled the introduction of innovative biologics specifically targeting the underlying causes of inflammatory bowel disease. Pfizer’s well-recognized brand and established distribution channels provide a competitive advantage, ensuring that its products reach a wide range of healthcare providers across South Korea.

    The company also benefits from a strong reputation for quality and efficacy in its medicines, strengthening its position in the marketplace. Additionally, Pfizer actively engages in local partnerships that enhance its ability to address the specific needs of South Korean patients.

    Ferring Pharmaceuticals also plays a significant role in the South Korean Inflammatory Bowel Disease Treatment Market, focusing on specialty care and innovative therapies. The company is known for its key products designed to support patients with inflammatory bowel diseases, and its strong market presence is reflected in its commitment to research-driven solutions.

    Ferring's strengths include a dedicated approach to patient-centric care and collaborations with local healthcare professionals to better understand the chronic conditions affecting the South Korean population. The company continually invests in clinical trials and product development to enhance its offerings.

    In recent years, Ferring Pharmaceuticals has engaged in strategic partnerships and acquisitions aimed at bolstering its presence and capabilities within the country. This proactive approach allows Ferring to stay competitive and responsive to evolving market needs, ensuring the provision of effective treatment options for patients in South Korea dealing with inflammatory bowel disease.

    Key Companies in the South Korea Inflammatory Bowel Disease Treatment Market market include

    Industry Developments

    Recent developments in the South Korea Inflammatory Bowel Disease Treatment Market have shown significant movement in 2023, with various pharmaceutical companies enhancing their presence. Pfizer, Merck, and AbbVie continue to lead with innovative treatments, directly impacting market growth.

    The launch of new therapies by Roche and Takeda Pharmaceutical in early 2023 has drawn increased attention and investment in the sector. Notably, in August 2023, Amgen announced its collaboration with Mylan to develop biosimilars for inflammatory bowel conditions.

    Additionally, Ferring Pharmaceuticals has initiated clinical trials for novel therapies, marking a substantial step forward in Research and Development efforts tailored for the South Korean demographic. The market has seen a valuation increase as a result of companies focusing on personalized medicine, which caters specifically to the unique genetic profiles of South Korean patients.

    Over the last two years, significant regulatory changes in May 2022 encouraged faster approvals for new treatments, which has facilitated a competitive landscape. This environment fosters innovation and collaboration, with players such as Johnson and Johnson and Bristol Myers Squibb actively exploring partnerships to enhance their product portfolios in the local market.

    Market Segmentation

    Inflammatory Bowel Disease Treatment Market End User Outlook

    • Hospitals
    • Ambulatory Surgical Centers
    • Homecare Settings

    Inflammatory Bowel Disease Treatment Market Drug Type Outlook

    • Aminosalicylates
    • Corticosteroids
    • Immunomodulators
    • Biologics
    • Antibiotics

    Inflammatory Bowel Disease Treatment Market Disease Type Outlook

    • Ulcerative Colitis
    • Crohn's Disease

    Inflammatory Bowel Disease Treatment Market Route of Administration Outlook

    • Oral
    • Injectable
    • Topical

    Report Scope

     
    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 409.0(USD Million)
    MARKET SIZE 2024 423.75(USD Million)
    MARKET SIZE 2035 625.0(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 3.596% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Pfizer, Ferring Pharmaceuticals, Astellas Pharma, Celgene, Sandoz, Mylan, Sanofi, Merck, Lupin Pharmaceuticals, Roche, AbbVie, Amgen, Takeda Pharmaceutical, BristolMyers Squibb, Johnson & Johnson
    SEGMENTS COVERED Drug Type, Route of Administration, Disease Type, End User
    KEY MARKET OPPORTUNITIES Increasing demand for biologic therapies, Growing telehealth adoption for management, Development of novel drug formulations, Rising prevalence of IBD, Enhanced patient education and support services
    KEY MARKET DYNAMICS rising prevalence of IBD, increasing healthcare expenditure, advancements in treatment options, growing awareness and diagnosis, government support for research
    COUNTRIES COVERED South Korea

    FAQs

    What is the projected market size of the South Korea Inflammatory Bowel Disease Treatment Market in 2024?

    The South Korea Inflammatory Bowel Disease Treatment Market is projected to reach a value of 423.75 million USD in 2024.

    What is the estimated market size of the South Korea Inflammatory Bowel Disease Treatment Market by 2035?

    By 2035, the South Korea Inflammatory Bowel Disease Treatment Market is expected to be valued at 625.0 million USD.

    What is the expected compound annual growth rate (CAGR) for the South Korea Inflammatory Bowel Disease Treatment Market from 2025 to 2035?

    The expected CAGR for the South Korea Inflammatory Bowel Disease Treatment Market from 2025 to 2035 is 3.596%.

    Which drug type is projected to have the highest market value in 2024 for the South Korea Inflammatory Bowel Disease Treatment Market?

    In 2024, Biologics is projected to have the highest market value at 150.0 million USD.

    What is the market size for Aminosalicylates in the South Korea Inflammatory Bowel Disease Treatment Market in 2035?

    The market size for Aminosalicylates is projected to reach 145.0 million USD by 2035.

    Who are the major players in the South Korea Inflammatory Bowel Disease Treatment Market?

    Major players in the market include Pfizer, AbbVie, Takeda Pharmaceutical, and Johnson & Johnson.

    What is the market value of Corticosteroids in the South Korea Inflammatory Bowel Disease Treatment Market for 2024?

    The market value of Corticosteroids is estimated to be 75.0 million USD in 2024.

    What challenges are currently impacting the South Korea Inflammatory Bowel Disease Treatment Market?

    Key challenges in the market include the high cost of treatment and variations in healthcare policies.

    What growth opportunity is anticipated for Immunomodulators in the South Korea Inflammatory Bowel Disease Treatment Market?

    Immunomodulators are expected to grow to a market value of 115.0 million USD by 2035.

    What is the projected growth rate for Antibiotics in the South Korea Inflammatory Bowel Disease Treatment Market from 2025 to 2035?

    The market for Antibiotics is expected to grow from 13.75 million USD in 2024 to 25.0 million USD in 2035.

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027